Evidence map›Paper›PMID 25675879›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2015

Neutralizing BAFF/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model.

J Kwun, E Page, J J Hong, A Gibby, J Yoon, A B Farris, F Villinger, S Knechtle

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Current perspective of immunomodulators for lung transplant.Indian journal of thoracic and cardiovascular surgery · 2022
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Donor apoptotic cell-based therapy for effective inhibition of donor-specific memory T and B cells to promote long-term allograft survival in allosensitized recipients.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020
    Article
  17. Experimental modeling of desensitization: What have we learned about preventing AMR?American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020
    Review
  18. Observational
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

J KwunDepartment of Surgery, Emory Transplant Center, Emory University School of Medicine, Atlanta, GA.
E Page
J J Hong
A Gibby
J Yoon
A B Farris
F Villinger
S Knechtle
Emory University · USEmory National Primate Research Center

Funding

Transplant Tolerance in Non-Human PrimatesU19AI051731 · NIAID · UNIVERSITY OF WESTERN ONTARIO · PI ADAMS, ANDREW B · 2002 to 2022
$54.1M
Memory and Regulatory T Cells Following T Cell Depletion in TransplantationU01AI074635 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI KNECHTLE, STUART JOHNSTON · 2007 to 2011
$3.5M
NIAID NIH HHS 1U01AI074635NIAID NIH HHS 2U19-AI051731NIAID NIH HHS U01 AI074635NIAID NIH HHS U19 AI051731
6 · The paper itself

Abstract

Depletional strategies directed toward achieving tolerance induction in organ transplantation have been associated with an increased incidence and risk of antibody-mediated rejection (AMR) and graft injury. Our clinical data suggest correlation of increased serum B cell activating factor/survival factor (BAFF) with increased risk of antibody-mediated rejection in alemtuzumab treated patients. In the present study, we tested the ability of BAFF blockade (TACI-Ig) in a nonhuman primate AMR model to prevent alloantibody production and prolong allograft survival. Three animals received the AMR inducing regimen (CD3-IT/alefacept/tacrolimus) with TACI-Ig (atacicept), compared to five control animals treated with the AMR inducing regimen only. TACI-Ig treatment lead to decreased levels of DSA in treated animals at 2 and 4 weeks posttransplantation (p < 0.05). In addition, peripheral B cell numbers were significantly lower at 6 weeks posttransplantation. However, it provided only a marginal increase in graft survival (59 ± 22 vs. 102 ± 47 days; p = 0.11). Histological analysis revealed a substantial reduction in findings typically associated with humoral rejection with atacicept treatment. More T cell rejection findings were observed with increased graft T cell infiltration in atacicept treatment, likely secondary to the graft prolongation. We show that BAFF/APRIL blockade using concomitant TACI-Ig treatment reduced the humoral portion of rejection in our depletion-induced preclinical AMR model.

Indexed as

Kidney TransplantationLymphocyte DepletionModels, AnimalAnimalsAntibodies, NeutralizingAntibody FormationB-Cell Activating FactorGraft SurvivalHumansMacaca mulattaMaleRecombinant Fusion ProteinsT-LymphocytesTumor Necrosis Factor Ligand Superfamily Member 13Antibodies, NeutralizingB-Cell Activating FactorRecombinant Fusion ProteinsTACI receptor-IgG Fc fragment fusion proteinTNFSF13B protein, humanTumor Necrosis Factor Ligand Superfamily Member 13alloantibodyanimal models: nonhuman primatebasic (laboratory) research/scienceB cell biologyimmunosuppression/immune modulationkidney transplantation/nephrologyrejection: antibody-mediated (ABMR)translational research/science

Identifiers

PMID25675879
PMCPMC5504528
OpenAlexW1759641455

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.